Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications

被引：0
|
作者：
Kolberg, H. C. [1 ]
Tomasevic, Z. [2 ]
Demetriou, G. S. [3 ]
Von Minckwitz, G. [4 ]
Fujiwara, Y. [5 ]
Ponomarova, O. [6 ]
Tesch, H. [7 ]
Santi, P. [8 ]
Hanes, V. [9 ]
机构：
[1] Marienhospital gGmbH, Klin Gynakol & Geburtshilfe, Bottrop, Germany
[2] Inst Oncol & Radiol Serbia, Oncol & Radiol, Belgrade, Serbia
[3] Charlotte Mexeke Johannesburg Acad Hosp, Div Med Oncol, Johannesburg, South Africa
[4] German Breast Grp, Neu Isenburg, Germany
[5] Natl Canc Ctr, Tokyo, Japan
[6] RE Kavetsky Inst Expt Pathol, Expt Pathol, Kiev, Ukraine
[7] Hamatol Onkol Gemeinschaftspraxis, Frankfurt, Germany
[8] Ctr Estudos Hematol & Oncol, Hematol & Oncol, Sao Paulo, Brazil
[9] Amgen Inc, Biosimilars Global Dev, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
365 (PB-16
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial
    F. J. Esteva
    Y. V. Baranau
    V. Baryash
    A. Manikhas
    V. Moiseyenko
    G. Dzagnidze
    E. Zhavrid
    D. Boliukh
    D. Stroyakovskiy
    J. Pikiel
    A. E. Eniu
    R. K. Li
    A. V. Rusyn
    B. Tiangco
    S. J. Lee
    S. Young Lee
    S. Y. Yu
    J. Stebbing
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 839 - 847
  • [42] Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study
    Georgoulias, V.
    Bozionelou, V.
    Agelaki, S.
    Perraki, M.
    Apostolaki, S.
    Kallergi, G.
    Kalbakis, K.
    Xyrafas, A.
    Mavroudis, D.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1744 - 1750
  • [43] Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
    Esteva, F. J.
    Baranau, Y.
    Baryash, V.
    Manikhas, A.
    Moiseyenko, V.
    Dzagnidze, G.
    Zhavrid, E.
    Boliukh, D.
    Stroyakovskiy, D.
    Pikiel, J.
    Eniu, A.
    Komov, D.
    Zautashvili, Z.
    Morar-Bolba, G.
    Li, R. K.
    Lifirenko, I.
    Rusyn, A.
    Lee, S. J.
    Yu, S.
    Stebbing, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
    Geyer, C. E., Jr.
    Huang, C-S
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Fischer, H. H.
    Redondo, A.
    Jackisch, C.
    Jacot, W.
    Conlin, A. K.
    Schneeweiss, A.
    Wapnir, I. L.
    Fasching, P. A.
    DiGiovanna, M. P.
    Wuelfing, P.
    Arce-Salinas, C.
    Crown, J. P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    von Minckwitz, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [45] Neoadjuvant trastuzumab emtansine and docetaxel, with or without pertuzumab, in patients with HER2-positive early-stage breast cancer: Results from a phase lb/2a study
    Martin, M.
    Dewar, J.
    Albanell, J.
    Limentani, S.
    Chang, J.
    Strasak, A.
    Patre, M.
    Garcia-Saenz, J. A.
    CANCER RESEARCH, 2013, 73
  • [46] Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
    Puhalla, Shannon
    Wilks, Sharon
    Brufsky, Adam
    O'Shaughnessy, Joyce
    Schwartzberg, Lee Steven
    Berrak, Erhan
    Song, James
    Cox, David
    Vandat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia The PEONY Phase 3 Randomized Clinical Trial
    Shao, Zhimin
    Pang, Da
    Yang, Hongjian
    Li, Wei
    Wang, Shusen
    Cui, Shude
    Liao, Ning
    Wang, Yongsheng
    Wang, Chuan
    Chang, Yuan-Ching
    Wang, Hweichung
    Kang, Seok Yun
    Seo, Jae Hong
    Shen, Kunwei
    Laohawiriyakamol, Suphawat
    Jiang, Zefei
    Li, Junjie
    Zhou, Julian
    Althaus, Betsy
    Mao, Yixiang
    Eng-Wong, Jennifer
    JAMA ONCOLOGY, 2020, 6 (03)
  • [48] Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.
    Pivot, Xavier
    Bondarenko, Igor
    Nowecki, Zbigniew
    Dvorkin, Mikhail
    Trishkina, Ekaterina
    Sarosiek, Tomasz
    Wojtukiewicz, Marek
    Shparyk, Yaroslav V.
    Moiseyenko, Vladimir
    Kim, Younsoo
    Lim, Jae Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] ADDITIONAL SAFETY RESULTS OF HANNAH: A PHASE III RANDOMISED, OPEN-LABEL, INTERNATIONAL STUDY OF THE SUBCUTANEOUS FORMULATION OF TRASTUZUMAB (H) IN HER2-POSITIVE EARLY BREAST CANCER PATIENTS
    Jackisch, C.
    Dank, M.
    Frasci, G.
    Park, K. H.
    Lopez, R. I.
    Johnston, M.
    Heinzmann, D.
    Weber, H.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 102 - 103
  • [50] 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
    Stebbing, J.
    Baranau, Y.
    Baryash, V.
    Manikhas, A.
    Moiseyenko, V.
    Dzagnidze, G.
    Zhavrid, E.
    Boliukh, D.
    Stroyakovskiy, D.
    Pikiel, J.
    Eniu, A.
    Komov, D.
    Lee, S. J.
    Kim, M. J.
    Kim, S.
    Park, S.
    Bae, J. H.
    Esteva, F. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 63 - +
12345